Trastuzumab Deruxtecan
FDA grants breakthrough status to T-DXd for two HER2-positive cancers
Anika Sharma
Daiichi Sankyo and AstraZeneca have garnered FDA Breakthrough Therapy Designations (BTDs) for their Enhertu (T-DXd) therapy to treat two distinct ...
Enhertu in Breast Cancer: A Breakthrough Treatment for HER2-Positive and HER2-Low
SG Tylor
This blog post will review how Enhertu in breast cancer works, how it is used, its benefits and risks, how ...
Maintaining Durable QOL in HER2+ Breast Cancer Patients: Trastuzumab Deruxtecan
SG Tylor
Results published in Annals of Oncology indicate that Trastuzumab deruxtecan (T-DXd; Enhertu) showed superior health-related quality-of-life (HRQOL) outcomes compared to ...
ASCO 2023: Patients with HER2-Positive MCRC Benefit from Lower Dose of Trastuzumab Deruxtecan
SG Tylor
ABSTRACT NUMBER – 3501 The Phase II DESTINY-CRC02 study, presented at the 2023 ASCO Annual Meeting, reported that administering ENHERTU ...
